6.1 Diagnostic Sleep Testing Modalities

6.1 Diagnostic Sleep Testing Modalities

Objective diagnostic testing is essential to confirm, characterize, and quantify sleep-related pathology. Clinical sleep health specialists must master the technical specifications, sensor montages, diagnostic capabilities, and clinical contraindications of each testing modality—ranging from fully attended in-laboratory polysomnography to ambulatory portable sleep apnea monitors, multi-nap objective sleepiness assessments, and longitudinal wrist actigraphy.

---

In-Laboratory Polysomnography (PSG) — Type 1

Type 1 In-Laboratory Polysomnography (PSG) is the comprehensive, attended diagnostic standard of reference in sleep medicine. Conducted overnight in an accredited sleep center under the continuous real-time supervision of a credentialed sleep technologist (RPSGT), Type 1 PSG monitors neurophysiologic, cardiorespiratory, and sensorimotor parameters simultaneously.

Mandatory Minimum Channel Montage (AASM Standards)

According to the American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events, a standard diagnostic Type 1 PSG requires a minimum of seven physiological parameter categories:

1. Electroencephalography (EEG):

   • Standard derivations include frontal (F4-M1), central (C4-M1), and occipital (O2-M1) electrodes, with contralateral backup electrodes (F3-M2, C3-M2, O1-M2).
   • Differentiates wakefulness, Stage N1, Stage N2 (sleep spindles and K-complexes), Stage N3 (slow-wave delta sleep), and Stage REM (low-voltage mixed-frequency EEG with saw-tooth waves).

2. Electrooculography (EOG):

   • Two electrodes placed 1 cm below the left outer canthus (E1-M2) and 1 cm above the right outer canthus (E2-M2), referenced to contralateral mastoids.
   • Detects slow rolling eye movements of sleep onset and rapid conjugate saccades characteristic of REM sleep.

3. Submental / Chin Electromyography (EMG):

   • Three electrodes (one midline, two submental) measuring baseline somatic muscle tone.
   • Essential for identifying the muscle atonia required for REM sleep scoring and diagnosing REM Sleep Behavior Disorder (RBD), where somatic atonia is pathologically absent.

4. Electrocardiography (ECG):

   • Single modified Lead II configuration recording cardiac rhythm and heart rate.
   • Evaluates sleep-disordered breathing arrhythmias, such as sinus bradycardia during apneic events, tachycardia upon arousal, and atrial fibrillation.

5. Airflow Sensors (Dual-Sensor Requirement):

   • Oronasal Thermal Sensor (Thermistor or Thermocouple): Measures convective thermal changes between exhaled warm air and room temperature. Designated as the primary sensor for detecting APNEAS (cessation of thermal airflow ≥90% for ≥10 seconds).
   • Nasal Air Pressure Transducer (Cannula): Measures pressure drops across inspiration and expiration. Designated as the primary sensor for detecting HYPOPNEAS (airflow reduction ≥30% for ≥10 seconds with desaturation or arousal) and flow limitation.

6. Respiratory Effort Belts (Dual Inductance Belts):

   • Thoracic and abdominal Respiratory Inductance Plethysmography (RIP) belts.
   • Crucial for distinguishing obstructive apneas (continued or increased respiratory effort with paradoxical thoracoabdominal motion) from central apneas (complete absence of thoracic and abdominal effort).

7. Pulse Oximetry:

   • Fast-response finger probe with an averaging time of ≤3 seconds to measure instantaneous arterial oxygen saturation ($SpO_2$) and quantify oxygen desaturation events.

8. Anterior Tibialis Electromyography (EMG):

   • Bilateral surface electrodes placed over the belly of the anterior tibialis muscles to detect periodic limb movements during sleep (PLMS).

9. Body Position Sensor & Video/Audio:

   • Continuous body position tracking (supine, lateral, prone, upright) and synchronized infrared video/audio recording for clinical correlation with parasomnias, seizure activity, and positional sleep apnea.

Clinical Indications for Type 1 PSG

• Suspected central sleep apnea, Cheyne-Stokes breathing, or obesity hypoventilation syndrome.
• Presence of significant cardiopulmonary disease (NYHA Class III-IV heart failure, severe COPD, pulmonary hypertension).
• Neuromuscular disease (ALS, myasthenia gravis) or stroke with residual neurological deficits.
• Suspected non-respiratory sleep disorders (narcolepsy, parasomnias, REM sleep behavior disorder, nocturnal seizures, periodic limb movement disorder).
• Pediatric patients (<18 years of age).
• Negative, ambiguous, or technically inadequate Home Sleep Apnea Testing (HSAT) in a symptomatic patient.

---

Home Sleep Apnea Testing (HSAT) — Types 2, 3, and 4

Portable monitoring technologies allow unattended sleep-disordered breathing assessment in the patient's home environment. Devices are classified based on channel composition:

Modality Classifications

• Type 2 (Comprehensive Portable): Unattended study recording ≥7 channels, including EEG, EOG, chin EMG, ECG, airflow, respiratory effort, and oximetry. Capable of scoring true sleep stages; rarely used in routine clinical practice due to high technical failure rates without a technologist present.
• Type 3 (Modified Portable Sleep Apnea Testing): The standard clinical HSAT. Records 4 to 7 channels, including airflow (nasal pressure), respiratory effort (RIP belt), pulse oximetry, and heart rate. Some validated systems incorporate Peripheral Arterial Tone (PAT) technology (e.g., WatchPAT), which utilizes finger plethysmography, pulse oximetry, actigraphy, and heart rate to detect sympathetic vascular tone surges and indirectly identify arousals and REM sleep.
• Type 4 (Continuous Single/Dual Bioparameter): Records only 1 or 2 parameters (typically pulse oximetry alone or oximetry with airflow/heart rate). Not recommended by the AASM for standalone OSA diagnosis due to high false-negative rates and inability to differentiate central from obstructive events.

Crucial Metric: REI vs. AHI

Because standard Type 3 HSAT does not record EEG, it cannot determine whether the patient is awake or asleep. Consequently:

• It cannot compute a true Apnea-Hypopnea Index (AHI), which requires dividing events by Total Sleep Time (TST).
• Instead, it calculates the Respiratory Event Index (REI): $\text{REI} = \frac{\text{Total Respiratory Events (Apneas + Hypopneas)}}{\text{Total Monitoring Time (or Valid Recording Time in Hours)}}$
• If a patient lies awake in bed for several hours during the recording, the monitoring time in the denominator is falsely inflated, systematically underestimating the severity of sleep-disordered breathing.

Clinical Indications and Exclusions for HSAT

• Clinical Indication: Used for uncomplicated adult patients with a high pre-test probability of moderate-to-severe OSA based on a comprehensive clinical sleep evaluation.
• When the 2017 AASM guideline recommends in-lab PSG instead of HSAT:
  1. Significant underlying cardiopulmonary disease (congestive heart failure, severe COPD, pulmonary arterial hypertension).
  2. Neuromuscular weakness or suspected hypoventilation.
  3. Chronic opioid medication use (high prevalence of central sleep apnea and ataxic breathing).
  4. History of stroke or transient ischemic attack with neurological sequelae.
  5. Suspected non-respiratory sleep disorders (narcolepsy, parasomnias, restless legs syndrome, periodic limb movements, chronic severe insomnia).
  6. Pediatric patients (<18 years).
  7. Environmental or cognitive impairment preventing independent application of equipment.

The same 2017 AASM guideline says a negative, inconclusive or technically inadequate HSAT in a symptomatic patient should be followed by in-lab PSG, and that questionnaires and prediction tools must not be used to diagnose OSA without PSG or HSAT.

---

Multiple Sleep Latency Test (MSLT)

The Multiple Sleep Latency Test (MSLT) is the standardized, objective neurophysiological test used to quantify daytime sleepiness and detect abnormal Sleep-Onset REM Periods (SOREMPs).

Protocol Requirements and Prerequisites

• Mandatory Preceding Overnight PSG: The patient must undergo an attended Type 1 in-laboratory PSG immediately preceding the daytime MSLT. The nocturnal PSG must document at least 6 hours (360 minutes) of sleep. This confirms that daytime sleepiness is not secondary to acute nocturnal sleep deprivation, untreated sleep apnea, or nocturnal disruption.
• Medication Discontinuation: REM-suppressing medications (such as SSRIs, SNRIs, tricyclic antidepressants, and MAOIs) should ideally be stopped at least 2 weeks before testing (or about 5 half-lives; long half-life drugs such as fluoxetine may need up to 6 weeks), only under the prescriber's direction.
• Toxicology Screening: A urine drug screen must be collected on the morning of testing to confirm the absence of stimulants, sedatives, or illicit substances that influence sleep latency or architecture.
• Prior Sleep Logs: The patient should keep a regular schedule with adequate sleep (at least 7 hours a night) for 1 to 2 weeks before testing, documented by a sleep diary and ideally actigraphy.

Test Protocol

• Consists of 5 nap opportunities at 2-hour intervals, the first starting 1.5 to 3 hours after the overnight recording ends. The AASM 2021 protocol allows stopping after 4 naps only when the result is already clearly diagnostic of narcolepsy.
• Standard montage: EEG, EOG, chin EMG, and ECG.
• Conducted in a dark, quiet, temperature-controlled room with the patient dressed in street clothes.
• Nap Duration Rules:
  • If no sleep occurs, the nap trial is terminated at 20 minutes, and sleep latency is recorded as 20.0 minutes.
  • If sleep occurs (defined as the first epoch of any sleep stage), the trial continues for exactly 15 minutes from the first sleep epoch to assess for the occurrence of REM sleep.

Diagnostic Criteria for Hypersomnolence

• Mean Sleep Latency (MSL): The average of the sleep onset latencies across all nap opportunities.
• Sleep-Onset REM Period (SOREMP): The emergence of REM sleep within 15 minutes of sleep onset.
• Narcolepsy (Type 1 and Type 2): Diagnostic criteria require:
  • Mean Sleep Latency ≤8.0 minutes; AND
  • ≥2 SOREMPs across the nap trials (or 1 SOREMP on MSLT plus 1 SOREMP on the preceding nocturnal PSG, where REM emerges within 15 minutes of nocturnal sleep onset).
• Idiopathic Hypersomnia: Diagnostic criteria require:
  • Mean Sleep Latency ≤8.0 minutes; AND
  • <2 SOREMPs (or documented total 24-hour sleep time ≥660 minutes on 24-hour continuous PSG or wrist actigraphy).
• Typical of healthy adults: a mean sleep latency above about 10 minutes; 8–10 minutes is a gray zone.

---

Maintenance of Wakefulness Test (MWT)

The Maintenance of Wakefulness Test (MWT) assesses an individual's objective ability to remain awake under soporific, sleep-inducing conditions. While the MSLT measures sleepiness, the MWT measures sustained alertness.

Protocol and Clinical Role

• Conducted across four 40-minute trials spaced at 2-hour intervals throughout the daytime.
• The patient sits in bed with the back and head supported in a dimly lit, quiet room, and is asked to sit still, look straight ahead (not directly at the light) and stay awake as long as possible. Extraordinary measures such as singing or slapping the face are not allowed.
• Standard recording montage: EEG, EOG, chin EMG, and ECG.
• Trial Termination: The trial ends after 40 minutes if no sleep occurs, or after unequivocal sleep onset (defined by AASM standards as three consecutive epochs of Stage N1 sleep or a single epoch of any other sleep stage).
• Clinical Indications: Evaluating the therapeutic efficacy of wake-promoting medications (modafinil, pitolisant, solriamfetol) or CPAP therapy, and performing fitness-for-duty determinations in safety-critical occupations (commercial motor vehicle drivers, airline pilots, rail engineers).
• Interpretation (AASM practice parameters): On the 40-minute protocol, a mean sleep latency under 8 minutes is abnormal. Values from 8 to 40 minutes are of uncertain significance; in normative data the average was about 30 minutes, and many healthy adults stayed awake for all four trials. Staying awake for all four trials gives the strongest, but not conclusive, evidence of the ability to stay awake. The MWT is one input to a fitness-for-duty decision, not a guarantee of safety.

---

Wrist Actigraphy

Wrist actigraphy employs a wrist-worn triaxial accelerometer that continuously logs physical movement counts in 30- or 60-second epochs over extended periods (typically ≥7 to 14 consecutive days). Validated scoring algorithms translate immobility into sleep and activity into wakefulness.

Clinical Indications

• Circadian Rhythm Sleep-Wake Disorders: Recommended objective tool (AASM 2018 actigraphy guideline) for diagnosing Delayed Sleep-Wake Phase Disorder (DSPD), Advanced Sleep-Wake Phase Disorder (ASPD), Non-24-Hour Sleep-Wake Rhythm Disorder, and Shift Work Disorder.
• Chronic Insomnia: Quantifies night-to-night variability in sleep schedules, estimates habitual total sleep time, and identifies sleep state misperception (paradoxical insomnia) by comparing recorded sleep against patient sleep diaries.
• Pre-MSLT Evaluation: Verifies regular sleep-wake schedules and confirms the absence of chronic sleep restriction for 1 to 2 weeks prior to narcolepsy testing.
• Limitations: Because actigraphy measures motion rather than brain activity, it overestimates sleep duration in patients lying quietly awake in bed (e.g., severe insomnia) and cannot stage sleep.

---

Comparative Diagnostic Modalities Table